[ XXXX spontaneous regression: clinical and histopathologic analysis].

@entity1 @entity5066 @entity231 @entity39 @entity5 @entity4 @entity2184 @entity194 @entity3 @entity995
OBJECTIVE: To analyze the clinicopathologic characteristics of @entity995 spontaneous regression. METHODS: Retrospective case series study. The clinic and pathologic data of 52 cases of @entity995 spontaneous regression were analyzed retrospectively. All the cases came from 579 cases of @entity995 (without pre-enucleation chemotherapy) archived in Ophthalmic Pathology Laboratory of Beijing Tongren Eye Centre from Jan. 2007 to Dec. 2013. The analyzed factors included @entity5 activity, @entity5 invasion, and tissue changes of uveal and lens. RESULTS: In this study, the @entity1 ' average age was (14.0    8.7) months. There were 33 (63.5%) male and 19 (36.5%) female @entity1 . The rate of @entity995 spontaneous regression was 9.0% (52/579), of which the rate of complete regression was 1.4% (8/579). The most common symptom was leucocoria coupled with red eye 55.8% (29/52). The typical clinicopathologic characteristics were as follows: (1) all or most of all @entity5 cells @entity39 and only @entity5 cell remains were left; (2)most eyeballs showed atrophiabulbi or phthisis bulbi; (3) severe @entity194 occurred in @entity2184 , especially in iris and ciliary body combined with pigment cells disintegrating; (4) @entity231 formed coupled with @entity4 , displacement, or wrapped by fibrous connective tissue; (5) in a small number of cases, there were alive @entity5 cells in the retrolaminar optic nerve or choroid in spite of most @entity5 cells had suffered regression, indicating the @entity1 had histopathologic high risk factors and had the dispositions of @entity5 diffusion and @entity3 . CONCLUSIONS: Some untypical clinical manifestation such as leukocoria coupled with red eye or @entity5066 bulbi should be paid close attention. The possibility of @entity995 spontaneous regression should be considered. Meanwhile, some cases of @entity995 spontaneous regression with histopathologic high risk factors should be given post-enucleation systemic adjuvant chemotherapy combined with close observations and follow-ups.
